Methods: Between April 2016 and November 2018, a total of 137 patients (118 males, 19 females; median age: 49 years; range, 40 to 54 years) with advanced heart failure who were candidates for left ventricular assist device implantation or heart transplantation were retrospectively analyzed. We developed a formula calculated by using the biochemical and cardiac catheterization parameters of the patients.
Results: There was a strong correlation between the right atrial pressure and the scores (r=0.510, p<0.001). The estimated right atrial pressure was calculated as "2 + (0.92 ¥ Model for End-Stage Liver Disease Score)" (unstandardized coefficient 0.920, t value 7.674, p<0.001). The Model for End-Stage Liver Disease score was found to be an independent predictor of high right atrial pressure (odds ratio=1.491, 95% confidence interval: 1.244-1.786, p<0.001). The calculated area under the curve was 0.789 (95% confidence interval: 0.710-0.867, p<0.001) and the cut-off value of the Model for End-Stage Liver Disease score in the prediction of high right atrial pressure was 10.5 with 75% sensitivity and 73% specificity.
Conclusion: We define a method to calculate right atrial pressure obtained by using the Model for End-Stage Liver Disease score without the need for cardiac catheterization during the hospitalization and follow-up period of patients with advanced heart failure.
The MELD scoring system, which was subsequently introduced in HF patients and has been shown to correlate with high-risk tricuspid valve surgery even in patients without primary liver disease was originally developed and validated to assess the short-term prognosis of patients undergoing the transjugular intrahepatic portosystemic shunt procedure.[3,4] Recently, it has been shown that a high MELD score is a prognostic factor in predicting death in heart transplant candidates, and a high pre-transplant MELD score (>20) is associated with an increased risk of morbidity and mortality in patients undergoing orthotopic heart transplantation.[5,6]
Increased central venous pressure, reflecting right atrial pressure (RAP), is associated with impaired renal function and all-cause mortality in a wide range of patients with cardiovascular disease, including HF.[7] Since a high RAP leads to hepatic and venous congestion, we aimed to demonstrate the association between RAP and the MELD score, as well as the ability of the MELD score to accurately predict the value of RAP obtained by cardiac catheterization in patients with advanced HF.
The standard MELD score was calculated using the following formula: MELD = 3.78×ln [serum bilirubin (mg/dL)] + 11.2×ln [INR] + 9.57×ln [serum creatinine (mg/dL)] + 6.43.
Cardiac catheterization
The patients underwent cardiac catheterization
during the period of evaluation to decide their candidacy
for LVAD implantation or heart transplantation at the
Heart Failure Department of our hospital. In the
catheter laboratory, continuous pressure monitoring
was used, and the catheter was inserted via the
femoral vein and positioned in the right heart and the
pulmonary arteries. The transducer was calibrated in
the middle of the chest. The observers were blinded to
all echocardiographic data. The RAP (mmHg), mean
pulmonary artery pressure, aortic blood pressure, and
left ventricular end-diastolic pressure were recorded
at the end of a normal expiration. The cardiac output
(CO, L/min) was calculated using the Fick method.
For all patients, RAP measurements were performed
during 5 to 10 cardiac cycles, and the mean value was
calculated.
Echocardiography
Transthoracic echocardiography was performed
with the IE 33 device (Philips Medical System,
Bothell, WA, USA) after the patient was placed in
the left lateral position, by using a 3 MHz transducer.
Linear internal measurements of the left ventricle were
made in the parasternal long-axis view. Values were
obtained carefully perpendicular to the left ventricular
long axis and measured at or just below the mitral valve
tips. Left ventricular ejection fraction was calculated
using the biplane disc method (modified Simpson's
rule). Tricuspid annular plane systolic excursion was measured by M-mode echocardiography with an
optimally aligned cursor along the direction of the
tricuspid lateral ring in apical four-chamber view. All
measurements were made by two trained cardiologists
blinded to invasive hemodynamics.
Statistical analysis
Statistical analysis was performed using the IBM
SPSS version 21.0 software (IBM Corp., Armonk, NY,
USA). Normally distributed data were presented in
mean ± standard deviation (SD), while non-normally distributed variables were presented in median
(min-max). Categorical variables were presented
in number and frequency. Univariate comparisons
between the groups were performed using the
chi-square test for categorical variables and Student
t-test or Mann-Whitney rank-sum test for continuous
variables, as appropriate. The correlation between the
variables was analyzed using the Pearson or Spearman
correlation coefficient. To estimate the independent
predictors of high RAP, a multiple logistic regression
model was performed for the variables with a p value
of <0.05 in the univariate analyses. Receiver operating
characteristic curves were plotted to determine the
optimal cut-off values for individual parameters to
predict high RAP and to establish the optimal cut-off
points for use in clinical decision-making. A p value of
<0.05 was considered statistically significant.
Table 1: Baseline and demographic characteristics of patients
The median value of the RAP was 12 (range, 8 to 16) mmHg and the median MELD score was 10 (range, 8 to 12). There was a good correlation between the RAP and the MELD score (r=0.510, p<0.001). In the linear regression analysis, the estimated RAP was calculated as follows: "2 + (0.92×MELD Score)"(Unstandardized coefficient 0.920, t value 7.674 and p<0.001) (Figure 1).
In addition, the correlation between the MELD score and RAP was higher in patients with ischemic cardiomyopathy than in non-ischemic individuals (r=0.569, p<0.001 vs. r =0.443, p <0.001). T he correlation coefficients between RAP and the parameters used in the calculation of the MELD score, such as total bilirubin, INR, and creatine, were 0.521 (p<0.001), 0.358 (p<0.001), and 0.251 (p=0.003), respectively (Figure 2a-c).
The patients were divided into two groups based on a RAP of 12 mmHg (Table 2). In patients with higher RAP, the ejection fraction was lower, tricuspid regurgitation was severe, and cardiac output and index were lower. In addition, left ventricular enddiastolic pressure, mean pulmonary artery pressure, and pulmonary vascular resistance were higher. The MELD score was also higher in patients with a higher RAP. In the logistic regression analyses, only the MELD score was found to be an independent predictor of high RAP (odds ratio [OR]=1.491, 95% confidence interval [CI]: 1.244-1.786, p<0.001) (Table 3). In the receiver operating characteristic curve analysis, the MELD score was used to estimate high RAP (>12 mmHg). The calculated area under the curve (AUC) was 0.789 (95% CI: 0.710-0.867, p<0.001), and the cut-off value for the MELD score in the prediction of high RAP was 10.5 (sensitivity and specificity was 75% and 73%, respectively) (Figure 3). The AUC values for total bilirubin, INR, and creatine, which are included in the MELD score, were 0.765 (0.681-0.849), 0.696 (0.608-0.784), and 0.621 (0.524-0.717), respectively.
The MELD, MELD-Na, and MELD-XI scores assess renal and hepatic dysfunction, which can be associated with death, cardiac transplantation, and ventricular assist device implantation in patients with advanced HF.[8,9]Abe et al.[10] showed an association between a high MELD-XI score in a modified form since the INR value and echocardiographic parameters of right ventricular dilatation and overload such as increased inferior vena cava diameter were not included. Patients with a high MELD-XI score had a higher risk for cholestasis right heart volume overload, and pulmonary arterial pressure. They argued that a high MELD-XI score was an independent predictor of cardiac death and all-cause death in patients with HF. In addition, Moraes[11] suggested that the use of MELD could contribute to the evaluation of the severity of HF in patients who are candidates for transplantation. This could help in setting up a system, similar to liver transplantation, of priority-based transplants for patients requiring a transplant at the earliest.[11]
Hepatic dysfunction in HF can be identified through a cholestatic profile, such as increased bilirubin, rather than a hepatitis (increased alanine aminotransferase and aspartate aminotransferase) profile; therefore, it has been suggested that the main targets are hepatocytes and biliary epithelium.[12] Backward obstruction of the central region of the hepatic lobule causes deposition of sinusoidal collagen and fibrosis of the septa. The sensitivity of the hepatocytes and biliary epithelium to an increased pressure due to lobular obstruction causes cholestatic bilirubin changes.[13]
It has been reported that the strongest hemodynamic determinant of an increase in creatinine levels and worsening renal failure is the presence of venous congestion as measured by elevated central venous pressure,[14] which also indicates an elevated RAP. Therefore, we attempted to determine the association between RAP obtained by right heart catheterization and the MELD score.
Adequate assessment of RAP is important for the management of patients with HF. Several methods have been proposed for the noninvasive estimation of RAP. It is usually estimated using two-dimensional echocardiographic parameters, such as the presence of inferior vena cava dilation and the degree of inspiratory inferior vena cava collapse.[15-20] In patients with acute decompensated HF, Patel et al.[21] suggested that the use of three-dimensional echocardiographic right atrial volume along with traditional two-dimensional echocardiographic parameters had an increased accuracy in detecting high RAP. However, according to the American Society of Echocardiography (ASE) criteria,[22] RAP can be classified as low (0-5 mmHg), normal (6-10 mmHg), or elevated (11-20 mmHg). In addition, Taniguchi et al.[23] suggested that liver stiffness, due to liver obstruction caused by RAP elevation, assessed using transient elastography, might provide a non-invasive diagnostic method to evaluate RAP in patients with HF.
In the present study, when we divided the participants with advanced HF into two groups according to the median value of RAP, the patients with higher RAP (>12 mmHg) had a lower cardiac output and cardiac index, as well as a higher left ventricular end-diastolic pressure and mean pulmonary artery pressure. Additionally, as expected, the MELD score was higher in patients with a high RAP. Although the degree of tricuspid regurgitation was higher in this group, it was not found to be a predictor of high RAP, indicating that RAP increases independently, irrespective of the degree of regurgitation. Patients with advanced HF may worsen, even with mild tricuspid regurgitation; this is an unexpected, yet interesting finding. We have also attempts to discover a rapid, non-invasive, and convenient bedside formula to predict high RAP.
Nonetheless, there are some limitations to this study. This is a single-center, retrospective study. In addition, blood sampling and non-invasive measurements were performed simultaneously. Cardiac catheterization was performed within 24 h of blood sampling and echocardiography. The MELD-XI score was not assessed. Also, brain natriuretic peptide values, main rhythm of the patient (atrial fibrillation or not) and hemoglobin values were not included in the study. Further studies including patients receiving warfarin treatment may be needed, particularly those with LVADs. However, this new formula should be validated in studies with a large number of patients with advanced HF, as well as in the general population to give a better representation of RAP.
In conclusion, adequate evaluation of right atrial pressure is important for the management of heart failure patients. Various methods have been proposed for the non-invasive estimation of right atrial pressure, usually using two-dimensional echocardiographic parameters. The Model for End-Stage Liver Disease score, which can be calculated by non-invasive methods, correlates with higher right atrial pressure measured using cardiac catheterization in patients with advanced heart failure. We describe a method to calculate the right atrial pressure obtained using the Model for End-Stage Liver Disease score in patients with advanced heart failure without the need for cardiac catheterization during hospitalization and follow-up.
Declaration of conflicting interests
The authors declared no conflicts of interest with respect to
the authorship and/or publication of this article.
Funding
The authors received no financial support for the research
and/or authorship of this article.
1) Kamath PS, Wiesner RH, Malinchoc M, Kremers W,
Therneau TM, Kosberg CL, et al. A model to predict
survival in patients with end-stage liver disease. Hepatology
2001;33:464-70.
2) Costa BP, Sousa FC, Serôdio M, Carvalho C. Value of
MELD and MELD-based indices in surgical risk evaluation
of cirrhotic patients: Retrospective analysis of 190 cases.
World J Surg 2009;33:1711-9.
3) Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J,
ter Borg PC. A model to predict poor survival in patients
undergoing transjugular intrahepatic portosystemic shunts.
Hepatology 2000;31:864-71.
4) Ailawadi G, Lapar DJ, Swenson BR, Siefert SA, Lau C, Kern
JA, et al. Model for end-stage liver disease predicts mortality
for tricuspid valve surgery. Ann Thorac Surg 2009;87:1460-7.
5) Szygu?a-Jurkiewicz B, Nadziakiewicz P, Zakliczynski M,
Szczurek W, Chraponski J, Zembala M, et al. Predictive
value of hepatic and renal dysfunction based on the
models for end-stage liver disease in patients with heart
failure evaluated for heart transplant. Transplant Proc
2016;48:1756-60.
6) Chokshi A, Cheema FH, Schaefle KJ, Jiang J, Collado
E, Shahzad K, et al. Hepatic dysfunction and survival
after orthotopic heart transplantation: Application of the
MELD scoring system for outcome prediction. J Heart Lung
Transplant 2012;31:591-600.
7) Damman K, van Deursen VM, Navis G, Voors AA, van
Veldhuisen DJ, Hillege HL. Increased central venous pressure
is associated with impaired renal function and mortality in a
broad spectrum of patients with cardiovascular disease. J Am
Coll Cardiol 2009;53:582-8.
8) Kim MS, Kato TS, Farr M, Wu C, Givens RC, Collado
E, et al. Hepatic dysfunction in ambulatory patients with
heart failure: Application of the MELD scoring system for
outcome prediction. J Am Coll Cardiol 2013;61:2253-61.
9) Scholfield M, Schabath MB, Guglin M. Longitudinal trends,
hemodynamic profiles, and prognostic value of abnormal
liver function tests in patients with acute decompensated
heart failure: An analysis of the ESCAPE trial. J Card Fail
2014;20:476-84.
10) Abe S, Yoshihisa A, Takiguchi M, Shimizu T, Nakamura Y,
Yamauchi H, et al. Liver dysfunction assessed by model for end-stage liver disease excluding INR (MELD-XI) scoring
system predicts adverse prognosis in heart failure. PLoS One
2014;9:e100618.
11) Moraes ACO, Fonseca-Neto OCLD. The use of meld score
(model for end-stage liver disease) and derivatives in cardiac
transplantation. Arq Bras Cir Dig 2018;31:e1370.
12) Lau GT, Tan HC, Kritharides L. Type of liver dysfunction
in heart failure and its relation to the severity of tricuspid
regurgitation. Am J Cardiol 2002;90:1405-9.
13) Kamath PS, Kim WR; Advanced Liver Disease Study Group.
The model for end-stage liver disease (MELD). Hepatology
2007;45:797-805.
14) Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO,
Starling RC, et at. Importance of venous congestion for
worsening of renal function in advanced decompensated
heart failure. J Am Coll Cardiol 2009;53:589-96.
15) Kircher BJ, Himelman RB, Schiller NB. Noninvasive
estimation of right atrial pressure from the inspiratory
collapse of the inferior vena cava. Am J Cardiol
1990;66:493-6.
16) Mintz GS, Kotler MN, Parry WR, Iskandrian AS, Kane
SA. Real-time inferior vena caval ultrasonography: Normal
and abnormal findings and its use in assessing right-heart
function. Circulation 1981;64:1018-25.
17) Brennan JM, Blair JE, Goonewardena S, Ronan A, Shah
D, Vasaiwala S, et al. Reappraisal of the use of inferior
vena cava for estimating right atrial pressure. J Am Soc
Echocardiogr 2007;20:857-61.
18) Brennan JM, Blair JE, Goonewardena S, Ronan A, Shah
D, Vasaiwala S, et al. A comparison by medicine residents
of physical examination versus hand-carried ultrasound
for estimation of right atrial pressure. Am J Cardiol
2007;99:1614-6.
19) Ommen SR, Nishimura RA, Hurrell DG, Klarich KW.
Assessment of right atrial pressure with 2-dimensional and
Doppler echocardiography: A simultaneous catheterization
and echocardiographic study. Mayo Clin Proc 2000;75:24-9.
20) Vourvouri EC, Schinkel AF, Roelandt JR, Boomsma F,
Sianos G, Bountioukos M, et al. Screening for left ventricular
dysfunction using a hand-carried cardiac ultrasound device.
Eur J Heart Fail 2003;5:767-74.
21) Patel AR, Alsheikh-Ali AA, Mukherjee J, Evangelista
A, Quraini D, Ordway LJ, et al. 3D echocardiography to
evaluate right atrial pressure in acutely decompensated
heart failure correlation with invasive hemodynamics. JACC
Cardiovasc Imaging 2011;4:938-45.